DK0914114T3 - Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A - Google Patents

Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A

Info

Publication number
DK0914114T3
DK0914114T3 DK97926449T DK97926449T DK0914114T3 DK 0914114 T3 DK0914114 T3 DK 0914114T3 DK 97926449 T DK97926449 T DK 97926449T DK 97926449 T DK97926449 T DK 97926449T DK 0914114 T3 DK0914114 T3 DK 0914114T3
Authority
DK
Denmark
Prior art keywords
mla
hypersensitivity
monophosphoryl lipid
methods
type
Prior art date
Application number
DK97926449T
Other languages
Danish (da)
English (en)
Inventor
Jerry Dolovich
J Terry Ulrich
Jean S Marshall
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of DK0914114T3 publication Critical patent/DK0914114T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK97926449T 1996-05-14 1997-05-08 Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A DK0914114T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/645,672 US5762943A (en) 1996-05-14 1996-05-14 Methods of treating type I hypersensitivity using monophosphoryl lipid A
PCT/US1997/007965 WO1997042947A1 (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
DK0914114T3 true DK0914114T3 (da) 2003-10-20

Family

ID=24589990

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97926449T DK0914114T3 (da) 1996-05-14 1997-05-08 Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A

Country Status (11)

Country Link
US (1) US5762943A (enExample)
EP (1) EP0914114B1 (enExample)
JP (1) JP4105230B2 (enExample)
AT (1) ATE249824T1 (enExample)
AU (1) AU3121497A (enExample)
CA (1) CA2252604C (enExample)
DE (1) DE69724970T2 (enExample)
DK (1) DK0914114T3 (enExample)
ES (1) ES2205231T3 (enExample)
PT (1) PT914114E (enExample)
WO (1) WO1997042947A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9724531D0 (en) * 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
EP1096954B1 (en) * 1998-07-14 2004-10-06 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid a
EP1671646A3 (en) * 1998-09-18 2007-08-29 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
ATE326239T1 (de) * 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
NZ515322A (en) * 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
HU230847B1 (en) * 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
GB0120150D0 (en) * 2001-08-17 2001-10-10 Glaxosmithkline Biolog Sa Novel compounds
DE10359351A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
EP2563390A4 (en) * 2010-04-30 2014-05-14 Allovate Llc METHOD AND ARTICLE FOR PREVENTING OR REDUCING THE RISK OF DEVELOPING A HYPERALGENIC IMMUNE SYSTEM
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2015112485A1 (en) * 2014-01-21 2015-07-30 Immune Design Corp. Compositions for use in the treatment of allergic conditions
CA2979523A1 (en) * 2015-05-01 2016-11-10 Nitto Denko Corporation Allergy vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
KR900701304A (ko) * 1988-05-05 1990-12-01 루이즈 츄이 콜린스 에이미 사람 및/또는 동물용 알레르겐 탈감작제
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
WO1993015766A1 (en) * 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens

Also Published As

Publication number Publication date
JP4105230B2 (ja) 2008-06-25
JP2000510844A (ja) 2000-08-22
DE69724970T2 (de) 2004-07-22
US5762943A (en) 1998-06-09
EP0914114A1 (en) 1999-05-12
ES2205231T3 (es) 2004-05-01
DE69724970D1 (de) 2003-10-23
EP0914114B1 (en) 2003-09-17
CA2252604C (en) 2009-09-08
AU3121497A (en) 1997-12-05
PT914114E (pt) 2004-02-27
WO1997042947A1 (en) 1997-11-20
CA2252604A1 (en) 1997-11-20
ATE249824T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
DK0914114T3 (da) Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
DE69435171D1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
DK0741744T3 (da) Immunogener mod gonadeotropinfrigørende hormon
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
RU94046145A (ru) Комбинированные вакцины, содержащие поверхностный антиген гепатита в и другие антигены, способ их получения, способ предупреждения инфекций гепатита в
AU2001295673A1 (en) Vaccine composition
AU4622693A (en) Potentiation of immunogenic response
DK0724431T3 (da) Fremgangsmåder og sammensætninger til mikroindkapsling af adjuvanser
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
DE69330752D1 (de) Unterdrückung proliferativer reaktionen und induktion von toleranz durch polymorphe typ ii-spezifische mhc allopeptide
NO964433L (no) Farmasöytiske preparater på basis av derivater av taxanklassen
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
NO955085L (no) Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
NO955084D0 (no) Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
AU5994596A (en) Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising fro m exposure to an antigen
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)
ATE210989T1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung